A Phase I/Ii Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-1909
Full Text
Open PDFAbstract
Available in full text
Date
April 5, 2019
Authors
Publisher
American Association for Cancer Research (AACR)